Rhythm Pharmaceuticals (NASDAQ: RYTM) — Company Overview, News & Financial Data
Rhythm Pharmaceuticals develops therapies for rare genetic diseases of obesity, aiming to improve patients' lives through innovative treatments.
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to transforming the lives of patients suffering from rare neuroendocrine diseases. The company focuses on the development and commercialization of therapies targeting the melanocortin-4 receptor pathway, a key biological pathway that regulates hunger, appetite, and body weight. Its primary commercial product is setmelanotide, marketed as IMCIVREE, an MC4R agonist approved for chronic weight management in pediatric and adult patients with specific rare genetic deficiencies, including Bardet-Biedl syndrome and hypothalamic obesity. Headquartered in Boston, Massachusetts, the company advances clinical research programs to address severe hyperphagia and rare obesity conditions globally.
Snapshot
Operations
Products and/or services of Rhythm Pharmaceuticals
- Commercial Product: Precision melanocortin-4 receptor agonist setmelanotide, marketed as IMCIVREE, designed to restore impaired MC4R pathway function and treat severe hyperphagia and obesity associated with rare genetic deficiencies including POMC, PCSK1, and LEPR.
- Expanded Approval Program: Global regulatory submissions and clinical evaluations expanding setmelanotide for adult and pediatric patients with acquired hypothalamic obesity, securing marketing authorizations across North American, European, and Asian pharmaceutical jurisdictions.
- Genetic Obesity Therapies: Commercial distribution and post-marketing clinical trials evaluating daily subcutaneous setmelanotide injections in pediatric and adult patients diagnosed with Bardet-Biedl syndrome across international markets to manage appetite and weight.
- Next-Generation MC4R Agonists: Development of novel small molecule melanocortin-4 receptor agonists, including investigational oral candidates and long-acting formulations, aimed at offering flexible dosing options for chronic rare neuroendocrine metabolic disorders.
- Early Research & Target Discovery: Preclinical and clinical discovery efforts aimed at identifying therapeutic candidates that target neuroendocrine pathways, focusing on restoring energy balance and hunger regulation in rare endocrine and metabolic conditions.
- Genetic Screening & Diagnostic Initiatives: Uncovering rare obesity programs and genetic testing initiatives providing healthcare providers with diagnostic panels to identify underlying genetic variants affecting the melanocortin pathway in hyperphagic patients.
Rhythm Pharmaceuticals executive team
- Dr. David P. Meeker M.D.Chairman, President & CEO
- Mr. Hunter C. Smith M.B.A.CFO & Treasurer
- Mr. Joseph ShulmanChief Technical Officer
- Mr. Yann MazabraudExecutive VP & Head of International
- Ms. Jennifer LeeExecutive VP & Head of North America
- Mr. Christopher P. GermanCorporate Controller & Principal Accounting Officer
- Dr. Alastair Garfield Ph.D.Chief Scientific Officer
- Mr. David ConnollyHead of Investor Relations & Corporate Communications
- Mr. Jim FlahertySenior VP & General Counsel
- Ms. Sarah RyanVice President of Sales & Marketing